United States Cell and Gene Therapy Manufacturing QC Market Size & Outlook, 2025-2033

United States Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, CAR-T, CAR-NK, B-Cell, Others, Gene Therapy, Viral, Non-viral), By Scale (Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-house Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Raw Material Testing, Vector Production, Other Workflows), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical / Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting (FACS), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others) and Forecasts, 2025-2033

Report Code: SRHI56482DR

Last Updated : Jul, 2025

Pages : 80

Author : Debashree Bora

Format : PDF, Excel

United States Cell and Gene Therapy Manufacturing QC Market, By Therapy Type (2021-2032)

United States Cell and Gene Therapy Manufacturing QC Market, By Scale (2021-2032)

United States Cell and Gene Therapy Manufacturing QC Market, By Mode (2021-2032)

United States Cell and Gene Therapy Manufacturing QC Market, By Workflow (2021-2032)

United States Cell and Gene Therapy Manufacturing QC Market, By Process (2021-2032)

United States Cell and Gene Therapy Manufacturing QC Market, By End-User (2021-2032)

Pharmaceutical Companies
1. Small Size
2. Medium Size
3. Large Size
Biopharmaceutical / Biotechnological Companies
1. Small Size
2. Medium Size
3. Large Size
Contract Manufacturing Organizations
1. Small Size
2. Medium Size
3. Large Size

United States Cell and Gene Therapy Manufacturing QC Market, By Technology Type (2021-2032)

Available for purchase with detailed segment data, forecasts, and regional insights.